Physician profile
Jeffrey A Bubis
NPI 1801891288
$75,455.90
in general payments reported to CMS, 2019-2025
73 companies · $12K in 2025
The $12K reported for 2025 was more than what 82% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,273 · 2020: $11K · 2021: $8,194 · 2022: $6,828 · 2023: $20K · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $4,801 · Honoraria: $4,616 · Travel and Lodging: $2,147 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,784.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $4,800.68 |
| Honoraria | $4,616.00 |
| Travel and Lodging | $2,147.12 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,442.15 | 2019-2025 | Enhertu, Imfinzi |
| Pfizer INC. | $9,571.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $8,265.79 | 2019-2025 | Kisqali |
| Blueprint Medicines Corporation | $7,455.96 | 2020-2023 | |
| Janssen Biotech, INC. | $4,897.29 | 2019-2025 | Tecvayli, Talvey, Carvykti |
| Jazz Pharmaceuticals INC. | $4,305.00 | 2021 | |
| Seagen INC. | $3,667.40 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Glaxosmithkline, LLC. | $3,503.05 | 2020-2025 | Ojjaara, Shingrix, Jemperli |
| Genzyme Corporation | $2,724.25 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $2,452.88 | 2020-2024 | Monoferric, Cosela |
| Astellas Pharma US INC | $2,417.62 | 2019-2025 | Padcev, Vyloy, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $2,219.39 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $1,677.02 | 2019-2024 | Tecentriq, Alecensa |
| Tersera Therapeutics LLC | $1,630.77 | 2022-2025 | Zoladex |
| Coherus Oncology, INC. | $1,088.00 | 2023 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $1,080.00 | 2023 | Orserdu |
| Aveo Pharmaceuticals, INC. | $934.76 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $821.90 | 2019-2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $622.70 | 2019-2025 | Keytruda, Lynparza |
| Beigene, LTD. | $500.00 | 2024 | Brukinsa |
| Beigene USA, INC. | $430.92 | 2021-2024 | Brukinsa |
| Gilead Sciences, INC. | $293.14 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $248.96 | 2019-2024 | Alunbrig, Fruzaqla |
| Amgen INC. | $239.43 | 2019-2025 | Blincyto, Kyprolis |
| Lilly USA, LLC | $234.34 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $179.42 | 2019-2025 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $172.81 | 2019-2025 | Enhertu |
| Abbvie INC. | $145.55 | 2020-2025 | Venclexta |
| Taiho Oncology, INC. | $143.63 | 2020-2025 | |
| Eisai INC. | $138.41 | 2019-2025 | |
| Emd Serono, INC. | $129.89 | 2019-2025 | |
| Kite Pharma, INC. | $117.55 | 2022-2024 | Yescarta |
| Novocure INC. | $114.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $110.49 | 2024-2025 | Libtayo, Lynozyfic |
| Array Biopharma INC | $110.16 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $106.13 | 2019-2025 | Onivyde, Somatuline Depot |
| Foundation Medicine, INC. | $104.77 | 2019-2020 | |
| Exelixis INC. | $102.35 | 2019-2025 | Cabometyx |
| Incyte Corporation | $88.27 | 2019-2025 | Monjuvi, Zynyz |
| Mirati Therapeutics, INC. | $85.91 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $71.87 | 2019 | |
| Global Blood Therapeutics, INC. | $67.03 | 2020-2022 | |
| Csl Behring | $48.91 | 2024 | Idelvion, Afstyla |
| Agios Pharmaceuticals, INC. | $46.38 | 2024-2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $42.43 | 2019-2024 | |
| Sobi, INC | $42.22 | 2025 | |
| Tesaro, INC. | $40.51 | 2019 | |
| Morphosys, US INC. | $39.08 | 2023-2024 | Monjuvi |
| G1 Therapeutics, INC. | $38.64 | 2023 | Cosela |
| Epizyme, INC. | $35.56 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $35.15 | 2023-2025 | Clonoseq |
| Lexicon Pharmaceuticals, INC. | $31.88 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.94 | 2019 | |
| Aurobindo Pharma USA, INC. | $25.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.56 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.21 | 2020 | |
| Fennec Pharmaceuticals, INC. | $24.07 | 2024 | Pedmark |
| Lundbeck LLC | $22.67 | 2020 | |
| Geron Corporation | $22.59 | 2025 | Rytelo |
| Apellis Pharmaceuticals, INC. | $21.30 | 2024 | Empaveli |
| Dova Pharmaceuticals | $18.60 | 2019 | |
| Emmaus Medical, INC. | $18.11 | 2019 | |
| Tg Therapeutics, INC. | $17.14 | 2022 | |
| Adc Therapeutics America, INC. | $16.65 | 2022 | |
| Immunocore Limited | $14.33 | 2024 | Kimmtrak |
| Puma Biotechnology, INC. | $13.42 | 2020 | |
| Karyopharm Therapeutics INC. | $13.08 | 2020 | |
| Deciphera Pharmaceuticals INC. | $12.70 | 2023 | Qinlock |
| Pharmacyclics LLC, An Abbvie Company | $11.70 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.06 | 2019 | |
| Veracyte, INC. | $1.64 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bubis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.